MX361355B - Uso del agonista del receptor tipo toll para el tratamiento del cáncer. - Google Patents
Uso del agonista del receptor tipo toll para el tratamiento del cáncer.Info
- Publication number
- MX361355B MX361355B MX2013007967A MX2013007967A MX361355B MX 361355 B MX361355 B MX 361355B MX 2013007967 A MX2013007967 A MX 2013007967A MX 2013007967 A MX2013007967 A MX 2013007967A MX 361355 B MX361355 B MX 361355B
- Authority
- MX
- Mexico
- Prior art keywords
- toll
- receptor agonist
- treating cancer
- present
- receptor
- Prior art date
Links
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 title abstract 3
- 239000003970 toll like receptor agonist Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 108010040721 Flagellin Proteins 0.000 abstract 1
- 102000008234 Toll-like receptor 5 Human genes 0.000 abstract 1
- 108010060812 Toll-like receptor 5 Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 231100000304 hepatotoxicity Toxicity 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000007056 liver toxicity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a métodos y agentes utilizados para tratar el cáncer en tejidos que expresan el receptor Tipo Toll 5, mediante la proporción de un agonista del receptor Tipo Toll tal como flagelina. La presente invención se refiere también a la protección del hígado de una toxicidad hepática utilizando un agonista del receptor Tipo Toll.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161431313P | 2011-01-10 | 2011-01-10 | |
PCT/US2012/020844 WO2012097012A1 (en) | 2011-01-10 | 2012-01-10 | Use of toll-like receptor agonist for treating cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013007967A MX2013007967A (es) | 2013-08-21 |
MX361355B true MX361355B (es) | 2018-12-04 |
Family
ID=46507417
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013007967A MX361355B (es) | 2011-01-10 | 2012-01-10 | Uso del agonista del receptor tipo toll para el tratamiento del cáncer. |
MX2018014998A MX2018014998A (es) | 2011-01-10 | 2013-07-08 | Uso del agonista del receptor tipo toll para el tratamiento del cancer. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018014998A MX2018014998A (es) | 2011-01-10 | 2013-07-08 | Uso del agonista del receptor tipo toll para el tratamiento del cancer. |
Country Status (15)
Country | Link |
---|---|
US (7) | US9376473B2 (es) |
EP (1) | EP2663367A4 (es) |
JP (1) | JP6041444B2 (es) |
KR (1) | KR20140030132A (es) |
CN (1) | CN103476458B (es) |
AU (1) | AU2012205681B2 (es) |
BR (1) | BR112013017283A2 (es) |
CA (1) | CA2824438A1 (es) |
CL (1) | CL2013002001A1 (es) |
CO (1) | CO6781506A2 (es) |
EA (1) | EA026524B1 (es) |
IL (1) | IL227308A (es) |
MX (2) | MX361355B (es) |
SG (1) | SG191830A1 (es) |
WO (1) | WO2012097012A1 (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
ES2727746T3 (es) | 2009-01-06 | 2019-10-18 | Galenagen Llc | Composiciones orales para el tratamiento o la prevención de infecciones por E. Coli |
JP5684725B2 (ja) | 2009-01-06 | 2015-03-18 | キュレロン リミテッド ライアビリティ カンパニー | 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法 |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
WO2011050135A1 (en) | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
MX361355B (es) * | 2011-01-10 | 2018-12-04 | Cleveland Biolabs Inc | Uso del agonista del receptor tipo toll para el tratamiento del cáncer. |
WO2012145651A2 (en) | 2011-04-21 | 2012-10-26 | Curemark, Llc | Compounds for the treatment of neuropsychiatric disorders |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
WO2014098649A1 (en) * | 2012-12-18 | 2014-06-26 | Obschestvo S Ogranichennoy Otvetstvennostyu "Panacela Labs" | Compositions and methods using toll-like receptor 5 and toll-like receptor agonist |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
CN104258375A (zh) * | 2014-09-18 | 2015-01-07 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 辐抗肽蛋白的新用途 |
SI3193901T1 (en) | 2014-12-23 | 2018-06-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
EP3395351A1 (en) | 2014-12-23 | 2018-10-31 | 4D Pharma Research Limited | Immune modulation |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
LT3206700T (lt) | 2015-06-15 | 2019-08-26 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterijų kamienus |
MX2017016529A (es) | 2015-06-15 | 2018-03-12 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas. |
KR20180012846A (ko) | 2015-06-15 | 2018-02-06 | 4디 파마 리서치 리미티드 | 박테리아 균주를 함유한 조성물 |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
LT3209310T (lt) | 2015-11-20 | 2018-04-25 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterinius kamienus |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
SG10201913557TA (en) | 2016-03-04 | 2020-02-27 | 4D Pharma Plc | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
WO2018112223A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
RU2650610C1 (ru) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
EP3630136B1 (en) | 2017-05-22 | 2021-04-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
TW201907931A (zh) | 2017-05-24 | 2019-03-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
TW201919670A (zh) | 2017-06-14 | 2019-06-01 | 英商4D製藥研究有限公司 | 包含細菌品系之組成物 |
CN111032061A (zh) | 2017-06-14 | 2020-04-17 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
UY37816A (es) | 2017-07-20 | 2019-02-28 | Spogen Biotech Inc | Polipéptidos bioactivos para mejorar la protección, crecimiento y productividad en plantas |
CN111886018A (zh) | 2018-03-19 | 2020-11-03 | 4D制药研究有限公司 | 组合物 |
CN108404113A (zh) * | 2018-05-16 | 2018-08-17 | 中国人民解放军军事科学院军事医学研究院 | 用于抗辐射损伤的口服辐抗肽药物组合物 |
CN108478782B (zh) * | 2018-05-16 | 2021-05-18 | 中国人民解放军军事科学院军事医学研究院 | 辐抗肽在促肝细胞再生中的应用 |
CN111109198B (zh) * | 2019-03-29 | 2021-08-20 | 成都华西海圻医药科技有限公司 | 一种葡萄膜炎动物模型构建方法 |
JP2022546465A (ja) * | 2019-08-30 | 2022-11-04 | ゲノム プロテクション,インコーポレイテッド | ワクチン有効性の増加方法 |
WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
JP2023504907A (ja) * | 2020-06-04 | 2023-02-07 | ザ カトリック ユニバーシティ オブ コリア インダストリー-アカデミック コーオペレイション ファウンデーション | フラジェリン由来のtlr5アゴニストを有効成分として含む抗がん剤組成物 |
AU2021300632A1 (en) | 2020-07-02 | 2023-02-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of achieving HIV viral remission using long-acting antiretroviral agents |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
KR102543157B1 (ko) * | 2020-11-16 | 2023-06-14 | 아주대학교산학협력단 | 톨-유사 수용체 1/2 및/또는 4 활성화 펩타이드 및 이의 용도 |
CN114592007B (zh) * | 2022-04-29 | 2023-10-27 | 昆明理工大学 | Far1基因的新用途 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3007812A (en) | 1957-02-11 | 1961-11-07 | Allied Chem | Water-repellent compositions, method of water-proofing porous surfaces therewith, and resulting water-repellent surfaces |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US5399494A (en) | 1983-03-04 | 1995-03-21 | The University Of Maryland System | Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom |
US6130082A (en) | 1988-05-05 | 2000-10-10 | American Cyanamid Company | Recombinant flagellin vaccines |
ES2088014T3 (es) | 1990-09-28 | 1996-08-01 | Sulzer Innotec Ag | Aguja hueca para utilizacion medica y procedimiento para la fabricacion de este tipo de agujas huecas. |
WO1993018150A1 (en) | 1992-03-02 | 1993-09-16 | Biocine S.P.A. | Helicobacter pylori proteins useful for vaccines and diagnostics |
US5693476A (en) | 1995-02-24 | 1997-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of screening for compounds capable of modulating vesicular release |
US20020009747A1 (en) | 1997-08-25 | 2002-01-24 | Freda Diane Miller | Methods and reagents for identifying modulators of neuronal apoptosis |
US5994409A (en) | 1997-12-09 | 1999-11-30 | U.S. Bioscience, Inc. | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
AU4709401A (en) | 1999-11-29 | 2001-06-12 | Inotek Corporation | Composition and method for treating a microbial infection |
JP2003527109A (ja) | 2000-01-31 | 2003-09-16 | ミューニン コーポレイション | ヒトcyr61 |
US7300749B2 (en) | 2000-02-17 | 2007-11-27 | Millennium Pharmaceuticals, Inc. | Molecules of the pyrin domain protein family and uses thereof |
AU2002216500A1 (en) | 2000-11-28 | 2002-06-11 | Genesis Research And Development Corporation Limited | Methods for modulating apoptotic cell death |
DE60141773D1 (de) | 2001-04-20 | 2010-05-20 | Inst Systems Biology | Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren |
US8703146B2 (en) | 2001-04-20 | 2014-04-22 | Institute For Systems Biology | Toll-like receptor 5 ligands and methods of use |
US20030077262A1 (en) | 2001-10-02 | 2003-04-24 | Guido Franzoso | Methods and compositions for modulating apoptosis |
US7078165B2 (en) | 2003-03-27 | 2006-07-18 | Institut Pasteur | Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof |
ATE483467T1 (de) | 2003-12-02 | 2010-10-15 | Cleveland Clinic Foundation | Verfahren zum schutz vor strahlung mit flagellin |
US7638485B2 (en) | 2003-12-02 | 2009-12-29 | Cleveland Biolabs, Inc. | Modulating apoptosis |
WO2005056041A2 (en) | 2003-12-02 | 2005-06-23 | Cleveland Clinic Foundation | METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ |
WO2005056054A2 (en) | 2003-12-02 | 2005-06-23 | Cleveland Clinic Foundation | METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB |
US20050266391A1 (en) | 2004-01-15 | 2005-12-01 | Bennett Brydon L | Methods for preserving tissue |
US7404963B2 (en) * | 2004-10-01 | 2008-07-29 | The University Of South Florida | Flagellin-based adjuvants and vaccines |
US7794731B2 (en) | 2004-12-16 | 2010-09-14 | Wake Forest University Health Sciences | Use of flagellin in the immunotherapy of Yersinia pestis |
US8007812B2 (en) | 2004-12-22 | 2011-08-30 | Cleveland Clinic Foundation | Flagellin related polypeptides and uses thereof |
JP2009507848A (ja) | 2005-09-09 | 2009-02-26 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 神経保護薬 |
US20070269406A1 (en) | 2005-12-14 | 2007-11-22 | Ichim Thomas E | Transcatheter tumor immunoembolization |
US20090081157A1 (en) * | 2006-01-09 | 2009-03-26 | Richard Syd Kornbluth | Immunostimulatory Combinations for Vaccine Adjuvants |
WO2008094275A1 (en) | 2007-01-30 | 2008-08-07 | New York University | Peptides for treatment of conditions associated with nitric oxide |
EP2170931A4 (en) * | 2007-06-15 | 2010-06-30 | Immurx Inc | USE OF TLR AGONISTS AND / OR TYPE 1 INTERFERONS TO MITIGATE THE TOXICITY OF THERAPEUTIC REGIMES OF TNF-R AGONISTS |
AU2008283802A1 (en) * | 2007-07-31 | 2009-02-05 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
EA201692127A1 (ru) * | 2007-11-07 | 2017-08-31 | Селлдекс Терапьютикс Инк. | Антитела, связывающиеся с человеческим dec-205 |
WO2009102818A1 (en) | 2008-02-11 | 2009-08-20 | Cleveland Biolabs, Inc. | Method for reducing the effects of chemotheraphy using flagellin related polypeptides |
EP2320948B1 (en) | 2008-08-01 | 2013-03-06 | Cleveland Biolabs, Inc. | Methods for treating reperfusion injuries |
WO2010133885A1 (en) | 2009-05-21 | 2010-11-25 | Astrazeneca Ab | Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases |
BR112012004806B8 (pt) | 2009-09-02 | 2022-10-04 | Novartis Ag | composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso |
CN104136614B (zh) | 2009-10-06 | 2018-04-06 | 帕纳塞拉实验室有限责任公司 | Toll‑样受体和激动剂用于治疗癌症的用途 |
MX361355B (es) * | 2011-01-10 | 2018-12-04 | Cleveland Biolabs Inc | Uso del agonista del receptor tipo toll para el tratamiento del cáncer. |
-
2012
- 2012-01-10 MX MX2013007967A patent/MX361355B/es active IP Right Grant
- 2012-01-10 WO PCT/US2012/020844 patent/WO2012097012A1/en active Application Filing
- 2012-01-10 SG SG2013051396A patent/SG191830A1/en unknown
- 2012-01-10 EP EP12734417.4A patent/EP2663367A4/en not_active Withdrawn
- 2012-01-10 KR KR1020137021035A patent/KR20140030132A/ko not_active Application Discontinuation
- 2012-01-10 BR BR112013017283A patent/BR112013017283A2/pt active Search and Examination
- 2012-01-10 CA CA2824438A patent/CA2824438A1/en not_active Abandoned
- 2012-01-10 AU AU2012205681A patent/AU2012205681B2/en not_active Ceased
- 2012-01-10 JP JP2013548628A patent/JP6041444B2/ja not_active Expired - Fee Related
- 2012-01-10 CN CN201280009451.0A patent/CN103476458B/zh not_active Expired - Fee Related
- 2012-01-10 EA EA201390843A patent/EA026524B1/ru not_active IP Right Cessation
- 2012-01-10 US US13/979,104 patent/US9376473B2/en active Active
-
2013
- 2013-07-03 IL IL227308A patent/IL227308A/en active IP Right Grant
- 2013-07-08 CL CL2013002001A patent/CL2013002001A1/es unknown
- 2013-07-08 MX MX2018014998A patent/MX2018014998A/es unknown
- 2013-07-29 CO CO13178553A patent/CO6781506A2/es not_active Application Discontinuation
-
2015
- 2015-11-23 US US14/949,441 patent/US20160206690A1/en not_active Abandoned
-
2016
- 2016-08-19 US US15/241,757 patent/US20170065692A1/en not_active Abandoned
-
2017
- 2017-06-23 US US15/631,427 patent/US10034926B2/en active Active
-
2018
- 2018-06-21 US US16/014,419 patent/US10265390B2/en active Active
-
2019
- 2019-02-19 US US16/279,457 patent/US10780152B2/en active Active
-
2020
- 2020-07-21 US US16/934,556 patent/US11628201B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018014998A (es) | Uso del agonista del receptor tipo toll para el tratamiento del cancer. | |
PH12017502141A1 (en) | Compounds and their methods of use | |
UA115983C2 (uk) | Інгібітори днк-пк | |
MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
IN2014KN00769A (es) | ||
EA201390085A1 (ru) | Композиции ингибиторов киназ для лечения рака | |
GEP201706695B (en) | Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases | |
IN2014MN02598A (es) | ||
UA108442C2 (ru) | Индазолы | |
MX349159B (es) | Derivados deuterados de ivacaftor. | |
IN2014MN00988A (es) | ||
TW201611725A (en) | Pest control agent | |
TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
MX2013013557A (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa. | |
IN2015DN01151A (es) | ||
MX360774B (es) | Antagonistas de progesterona. | |
PH12015501175A1 (en) | Substituted pyridopyrazines as syk inhibitors | |
PH12015501038A1 (en) | Inhibitors of iap | |
TN2012000469A1 (en) | Use of novel pan-cdk inhibitors for treating tumors | |
SG10202100921YA (en) | Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy | |
UA115583C2 (uk) | Азетидинілоксифенілпіролідинові сполуки | |
MX2015008187A (es) | Inhibidores de alk deuterados. | |
IN2015DN01329A (es) | ||
AU2013347232A8 (en) | 3-Aminocyclopentane carboxamide derivatives | |
AR087114A1 (es) | Uso del agonista del receptor tipo toll para el tratamiento del cancer, metodo de tratamiento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |